Document is current
Any future updates will be listed below
-
Authors
Haack, Lars
Krug, David
Rodler, Severin
Nuhn, Philipp
van der Horst, Christof
Schulz, Christian
Wittenstein, Olaf
Schmalz, Claudia
Blanck, Oliver
Siebert, Frank-André
Fabian, Alexander
-
Funding
Funding for this research was provided by:
Universitätsklinikum Schleswig-Holstein - Campus Kiel
- License Information
-
More Information
Article History
Received: 12 January 2025
Accepted: 1 April 2025
First Online: 9 April 2025
Declarations
:
: AF has received honoraria from Merck Sharp & Dohme outside the field of this work. DK has received honoraria from Astra Zeneca, best practice onkologie, ESO, ESMO, Gilead, med update, Merck Sharp & Dohme, Novartis, onkowissen, and Pfizer, as well as research funding from Stiftung Deutsche Krebshilfe and Merck KGaA. OW received honoraria and travel grants from Brainlab AG and novocure AG. SR has received honoraria from BMS, Merck, MSD and Novartis and has equity interest in Rocketlane Medical Ventures GmbH. All other authors declare no conflicts of interest. All other authors declare no conflicts of interest.
: Ethical approval was obtained from the local committee prior to enrolment of the first patient (Kiel, Germany D505/23).
: Written informed consent was obtained from each participating study patient.
